Arvinas Inc. (ARVN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Arvinas, Inc. (ARVN) Q4 2025 Earnings Call Transcript
Arvinas, Inc. (ARVN) Q4 2025 Earnings Call Transcript
Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates
Arvinas, Inc. (ARVN) came out with a quarterly loss of $1.1 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to a loss of $0.63 per share a year ago.
Arvinas, Inc. (ARVN) Q3 2025 Earnings Call Transcript
Arvinas, Inc. ( ARVN ) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Jeff Boyle - Vice President of Investor Relations John Houston - Chairperson, CEO & President Noah Berkowitz - Chief Medical Officer Angela Cacace - Chief Scientific Officer Andrew Saik - CFO & Treasurer Conference Call Participants Etzer Darout - Barclays Bank PLC, Research Division Jeet Mukherjee - BTIG, LLC, Research Division Li Wang Watsek - Cantor Fitzgerald & Co., Research Division Srikripa Devarakonda - Truist Securities, Inc., Research Division Tazeen Ahmad - BofA Securities, Research Division Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Jonathan Miller - Evercore ISI Institutional Equities, Research Division Presentation Operator Thank you for standing by, and welcome to Arvinas Third Quarter 2025 Earnings Call. I'd like to remind everyone that this call is being recorded.
Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Arvinas (ARVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arvinas, Inc. (ARVN) Q2 2025 Earnings Call Transcript
Arvinas, Inc. (NASDAQ:ARVN ) Q2 2025 Earnings Call August 6, 2025 8:00 AM ET Company Participants Andrew R. Saik - CFO & Treasurer Angela M.
Arvinas, Inc. (ARVN) Reports Q2 Loss, Misses Revenue Estimates
Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to a loss of $0.49 per share a year ago.
Wall Street Analysts Believe Arvinas (ARVN) Could Rally 89.85%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 89.9% in Arvinas (ARVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Arvinas: Yet Another Biotech Trading Below Net Cash, But It's Only A Mild Bull Case
I favor biotech stocks trading below cash value after setbacks; Arvinas (ARVN) fits this description, dropping 25% on Thursday after ending two Phase 3 trials. ARVN's net cash per share is over $12, presenting a 70% upside from its current $7 stock price. ARVN's remaining pipeline holds minimal value; the investment thesis hinges on its substantial cash reserves and potential for activist shareholder intervention.
Arvinas, Inc. (ARVN) Q1 2025 Earnings Call Transcript
Arvinas, Inc. (NASDAQ:ARVN ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Jeff Boyle - Vice President of Investor Relations John Houston - President and Chief Executive Officer Noah Berkowitz - Chief Medical Officer Andrew Saik - Chief Financial Officer Conference Call Participants Michael Schmidt - Guggenheim Andrew Berens - Leerink Partners Jonathan Miller - Evercore ISI Tazeen Ahmad - Bank of America Peter Lawson - Barclays Paul Choi - Goldman Sachs Srikripa Devarakonda - Truist Securities Yigal Nochomovitz - Citi Group Li Watsek - Cantor Fitzgerald Jeet Mukherjee - BTIG Sudan Loganathan - Stephens, Inc Operator Thank you for standing by. My name is Gail and I will be the operator for today's call.
Arvinas, Inc. (ARVN) Q1 Earnings and Revenues Beat Estimates
Arvinas, Inc. (ARVN) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of a loss of $0.86 per share. This compares to loss of $0.97 per share a year ago.
After Plunging -25.42% in 4 Weeks, Here's Why the Trend Might Reverse for Arvinas (ARVN)
The heavy selling pressure might have exhausted for Arvinas (ARVN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study
Arvinas, Inc. ARVN unveiled first-in-human data on Friday for its experimental Parkinson's disease treatment, ARV-102.
